Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J. Landovitz, Joseph J. Eron, Paul Richardson et al.|PLoS Medicine|2018Cited by 171
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialRaphael J. Landovitz, Craig W. Hendrix, Sue Li et al.|The Lancet HIV|2020Cited by 171
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077Elizabeth E. Tolley, Raphael J. Landovitz, Sahar Z. Zangeneh et al.|AIDS and Behavior|2020Cited by 92
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Helen Rees, Jinal N. Bhiman et al.|PLOS Global Public Health|2024Cited by 12
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Helen Rees, Jinal N. Bhiman et al.|medRxiv|2023Cited by 5